

# Subject Index

- A**ctive specific immunotherapy  
 for colorectal carcinoma, 135-145  
 of colon adenocarcinoma, 331  
 of Hodgkin's lymphoma, 352-354  
 of melanoma, 120, 147, 153-164, 167, 178, 190, 204, 214  
 Adenocarcinoma, colon, active specific immunotherapy of, 331  
 Adenovirus, 14  
 Adjuvants  
   in breast cancer, 276-290  
   in experimental malaria and AIDS vaccines, 268-273  
   QS-21, 392-395  
   tumor vaccines with, 303  
 AIDS vaccine  
   experimental, 265-274  
   progress in, 12-13  
 Alpha-interferon augments tumor immunogenicity, 388-391  
 ALVAC HIV recombinant virus, 295  
 Anti-antiidiotypic mAb and melanoma cell binding, 398-401  
 Anti-idiotype vaccine in Hodgkin-associated CD30 antigen, 352-354  
 Anti-idiotypic antibodies in antigen mimicry, 213-221  
 Antibodies  
   monoclonal, to gangliosides, 54-55  
   serum, to gangliosides, 52-54  
 Antigenic mutations in tumor evasion of immune response, 46-49  
 Antigens  
   as targets for active immunization, 24-31  
   carbohydrate, TA3-Ha tumor for analysis of, 73  
   carcinoembryonic, vaccinia virus expressing, 370-373  
   colon tumor-associated, 374-375  
   detected by immune responses in man, 51  
   differentiation, of melanocytes and melanoma, 62  
   Epstein-Barr virus, as targets for immune attack, 86-96  
   for tumor rejection, cancer immunotherapy with, 115-118  
   genetically modified, as immunogens, 29-30  
   HLA-A, melanoma cell vaccine expressing, 343-345  
   Hodgkin-associated CD30, anti-idiotype vaccine in, 352  
   immunogenic tumor, in man, 50-55  
   melanoma  
     biochemical and molecular studies of, 64-65  
     recognized by autoantibodies, 63, 190  
     melanoma-associated, 121, 163, 194-196  
     mimicry by anti-idiotypic antibodies, 214-221  
     pancarcinoma T/Tn, detects carcinoma, 355-357  
     shed antigens, 190  
     tissue-specific, and tolerance, 60  
     to cytolytic T lymphocytes, 113-118  
     tumor, 323-328  
       in breast cancer, 340-342  
       in humans, 27-29  
     tumor rejection, in colorectal carcinoma, 135-145  
     tumor-associated, immunization against, 337-339  
     tumor-specific, recognized by T cells, 301-302  
     viral, expression of, in EBV-infected cells, 86-89  
 Antiidiotype vaccine therapy for T-cell lymphoma, 376-377  
 Antiidiotypic antibodies as immunogens, 30, 214, 352, 385  
 ASI, *See* Active specific immunotherapy  
 Autoantibodies, 60-61  
   and autoreactive T cells in melanoma, 61  
   recognizing melanoma antigens, 63  
   studies of, 62  
 Autoantigens, recognition of, in melanoma, 59-66  
 Autoimmune disease, 19-22  
 Autoimmunity, 3  
   lessons from, 19-23
- B** lymphocytes, tolerance within, 38-39  
 B-cell lymphoma, idiotype-specific vaccine in, 385-387  
 B-cell tolerance, 37-38  
 B7 as costimulatory molecule, 30  
   in tumor immunity, 225-229  
 B7 gene introduced into tumor cells, 304-305  
 Bacillus Calmette-Guérin vaccine in colorectal carcinoma, 135-145  
 BCG, *See* Bacillus Calmette-Guérin  
 Bcr-abl protein, immunity to, 107-109  
 Breast cancer  
   immunization in, 276-290  
   recurrence of, vaccine to prevent, 355-357  
   tumor antigens in, 340-342  
 Burkitt's lymphoma, 42

- C**ancer, *See also* Carcinoma  
 breast  
   immunization in, 276-290  
   tumor antigens in, 340-342  
 colorectal, 334-335  
   immunotherapy  
     using poxvirus vectors, 292-298  
     with antigens for tumor rejection, 115-118  
   of viral etiology, vaccines for, 311-319  
   synthetic B human chorionic gonadotropin vaccine in, 358  
 Cancer Immunology Branch, NCI, on cancer vaccines, 322-329  
 Cancer vaccine adjuvant, QS-21 as, 392-395  
 Cancer vaccines, 322-329  
   design strategies, 190-191  
 Cancer viruses  
   in animals, 8  
   in man, 9-14  
 Carcinoembryonic antigen, vaccinia virus expressing, 370-373  
 Carcinoma  
   breast, recurrent, vaccine to prevent, 355-357  
   colorectal, adjuvant vaccination in, 360-362  
     monoclonal antibodies in, 337-339  
   renal cell, adjuvant immunotherapy in, 367-369  
 Carcinoma-derived cell line, HLA expression in, 42-43  
 CD4<sup>+</sup> helper/inducer T cells and synthetic ras peptides, 102-104  
 Cell-based immunotherapy using poxvirus-based vectors, 297-298  
 Cellular antigens in cancer host, recognition of, 59  
 Cervical cancer vaccine, prospects for, 80-83  
 Cervical carcinoma-derived cell line (Hela), typed, 45-46  
 Chromosome 9p22-23 mapped to gp75 gene, 66  
 Colon adenocarcinoma, active specific immunotherapy of, 331  
 Colon tumor-associated antigen, 374-375  
 Colorectal carcinoma  
   adjuvant vaccination in, 360-362  
   immunotherapy for, 135-145  
   monoclonal antibodies in, 334-335, 337-339  
   specific immunotherapy of, 364-366  
 Colorectal carcinoma-derived cell lines, 43-46  
 Costimulation in tumor immunity, 225-229  
 Costimulatory molecules  
   in immune response, 27, 29  
   in tumor immunity, 30  
 Cross-reactive idiotypes (CRIDs), 22  
 Cyclophosphamide in immunotherapy, 30  
 Cytokine genes introduced into tumor cells, 305-306  
 Cytolytic T cells, cloning of, 233
- D**audi, Burkitt's lymphoma-derived cell line, 42  
 Dendritic cell immune response to B-cell lymphoma, 382-384  
 Depigmentation in melanoma, 61  
 Detox  
   and keyhole limpet hemocyanin in breast cancer, 276-290  
   in advanced melanoma, 155-157  
 DNP vaccine therapy in melanoma, 148-149
- E**BNA, 87-88, 90-91  
 EBV, *See also* Epstein-Barr virus  
 EBV-associated malignancies and T-cell surveillance, 93-96  
 EBV-infected cells, T-cell surveillance of, 89-92  
 Effector T cells in tumor rejection, 26  
 Engineered vaccines, 244-253, 256-262, 301-308  
 Epitope selection and design of synthetic vaccines, 256-262  
 Epstein-Barr virus, 13  
   antigens as targets for immune attack, 86-96  
   studies of, 318-319
- G**amma-interferon and interleukin-2 in tumor immunity, 349-351  
 Ganglioside expression  
   in melanoma, 396-397  
   in tumors, 51-52  
 Gangliosides  
   as targets of immunotherapy, 204  
   monoclonal antibodies to, 54-55  
   serum antibodies to, 52-54  
 GD3-conjugate vaccines, immunogenic, 396-397  
 Gene coding antigens, 113  
   for lung tumor, 114-115  
 Genetically engineered tumor vaccines, 244-253, 256-262, 301-308  
 Genital papillomavirus infections, immune response to, 80-83  
 Glycosylation  
   aberrant, of PEM, 76-77  
   of mucins, 69-71  
 gp75 antigen  
   as human homolog of mouse *b* locus product, 65-66

as melanosome membrane glycoprotein, 64  
expression in melanocytic cells, 64  
of human melanoma cells, 63-64  
gp75 gene, chromosomal mapping of, 66

## Hapten-modified vaccine in melanoma, 147-151

Hela cell line, typed, 45-46  
Hepatitis B vaccine, 10-12  
Hepatitis C virus, 13, 318-319  
HIV vaccine development, 257  
HLA expression in carcinoma-derived cell lines, 42-43  
HLA phenotypes and melanoma immunotherapy, 160-161  
HLA-A antigens, melanoma cell vaccine expressing, 343-345  
Hodgkin's lymphoma, active specific immunotherapy of, 352-354  
HPV16 and immunity, 28-29

## Idiotypic-specific vaccine in B-cell lymphoma, 385-387

IgG antibody response to melanoma ganglioside vaccines, 204-211  
Immune attack, EBV antigens as targets for, 86-96  
Immune response  
  antitumor, immune tolerance in, 302-303  
  to genital papillomavirus infections, 80-83  
Immune system, polymorphic epithelial mucin as target for, 71-72  
Immune tolerance, 59-60  
Immunity, T-cell, to oncogenic proteins, 101-110  
Immunization  
  in breast cancer therapy, 342  
  in colorectal cancer, 334-335  
  with monoclonal antibodies in cancer, 337-339  
Immunogenicity, enhanced, genetic alteration of tumors for, 304  
Immunotherapy  
  active vs passive, 244-253  
  adjuvant, in renal cancer, 367-369  
  polymorphic epithelial mucin as target for, 69-77  
  specific, of colorectal carcinoma, 364-366  
  with vaccinia virus expressing CEA, 370-373  
Infections, genital papillomavirus, immune response to, 80-83  
Infectious diseases, vaccines against, 3

Interleukin-2  
  and gamma-interferon in tumor immunity, 349-351  
  transfection of tumors with, 346-348  
Interleukin-2-infected tumor cell vaccines, 331

## Keyhole limpet hemocyanin plus Detox in breast cancer, 276-290

Leukemia, feline, vaccines for, 9  
Liver metastasis, immunotherapy with tumor cells, 364-366

Lymphocytes in tumor rejection, 26-28

## Lymphoma

### B-cell

  dendritic cell immune response to, 382-384  
  idiotype-specific vaccine in, 385-387  
  T-cell, antiidiotype vaccine therapy for, 376-377

### Lysates

  allogeneic cell, in melanoma immunotherapy, 155-157  
  viral, as therapeutic vaccines in melanoma, 167-176

Malaria vaccine, experimental, 265-274  
Marek's disease, vaccine for, 9

MCV, *See* Melanoma cell vaccine

Melanocytes, autoimmune response against, in melanoma, 61

## Melanoma

  active specific immunotherapy of, 120, 147, 153-164, 167, 178, 190, 204, 214  
  and melanocytes, differentiation antigens of, 62  
  antigen vaccine from shed antigens, 190-202  
  antigens  
    biochemical and molecular studies of, 64-65  
    recognized by autoantibodies, 63  
  autoantibodies and autoreactive T cells in, 61  
  cell vaccine  
    augmenting T-cell response with, 343-345  
    for metastatic melanoma, 120-132  
  cells  
    binding parameters to, 398-401  
    gp75 antigen system of, 63-64  
    pigmentation in, 61  
    ganglioside vaccines, IgG antibody response to, 204-211  
  melanocytes and melanosomes, 61-62  
  prevention with vaccines, 201-202

- recognition of autoantigens in, 59-66  
 theraccine, allogeneic, 154-155  
 therapeutic vaccines in, 167-176  
 vaccine, 147-151  
   alpha-interferon and, 388-391  
   surrogate marker of efficacy for, 378-380  
   vaccinia melanoma oncolysate for, 178-187  
 Melanoma-associated antigens, 180-181  
 Melanosomes, biogenesis of, 64-65  
 Monoclonal antibodies  
   against tumor antigens in cancer, 337-339  
   and melanoma cell binding, 398-401  
   antiidiotypic, 216-218  
   human, 62  
   to gangliosides, 54-55  
 Monoclonal antiidiotypic antibody in  
   colorectal cancer, 334-335  
 Mucin  
   glycosylation of, 69-71  
   in normal and malignant tissues, 71  
   molecule, T-cell recognition of, 231-241  
   polymorphic epithelial  
     as target for immunotherapy, 69-77  
     in cancer patients, 72-73  
 MUC1 gene, human, transgenic mice  
   expressing, 73-75  
 Mutations, antigenic, in tumor escape of  
   immune response, 46-49

**N**ational Cancer Institute perspective on  
 cancer vaccines, 322-329  
 Newcastle-disease virus-modified autologous  
 tumor cells, 364-366  
 NYVAC HIV recombinant virus, 295

**O**ncogenes, mutated, in tumor rejection, 29  
 Oncogenic proteins, T-cell immunity to,  
 101-110

**P**21ras protein elicits immune T cells, 104  
 Pancarcinoma T/Tn antigen detects  
   carcinoma, 355-357  
 Papillomavirus infections, genital, immune  
   response to, 80-83  
 Papillomaviruses, 14  
   causative role of, in human tumors, 28-29  
   studies of, 317-319  
 PEM, *See* Polymorphic epithelial mucin  
 Peptides, synthetic  
   bind to class I MHC molecules, 106  
   immunogenicity studies using, 75-76  
 Polyclonal anti-idiotypic antibodies, 214-215  
 Polymorphic epithelial mucin  
   as target for immunotherapy, 67-77  
   in cancer patients, 72-73

Poxvirus vectors in cancer immunotherapy,  
 292-298  
 Proteins  
   cancer-specific, as tumor-specific antigens,  
   109  
   oncogenic, 101-110

**Q**S-21 isomers, adjuvant activity of,  
 392-395

**R**as mutations in tumors, 102  
 Ras p21 protein antibody detected in colon  
   cancer, 105  
 Ras peptide, tumors elicit T cells for, 105  
 Ras peptide-specific T cells respond to  
   parental protein, 104  
 Ras proteins, immunity to, 102  
 Rejection antigens, tumor-specific, 25  
 Renal cancer, adjuvant immunotherapy in,  
 367-369  
 Retroviruses, 12-13  
 Rodents, tumor rejection and immune  
   response to PEM in, 73

**S**erum antibodies to gangliosides, 52-54  
 Sialyl-Tn, synthetic, and KLH plus Detox in  
   breast cancer, 276-290  
 Simian immunodeficiency disease, vaccine  
   for, 9  
 Simian immunodeficiency virus vaccine,  
   experimental, 268-273  
 Simian virus 40 vaccine, 8-9


**T** cells  
   autoreactive, and autoantibodies in  
     melanoma, 61  
   CD4<sup>+</sup>, and synthetic *ras* peptides, 102-104  
   cytotoxic, specific for *ras* peptides, 107  
   effector, in tumor rejection, 26  
   in melanoma cell vaccine, 343-345  
   *ras* peptide-specific, respond to p21ras  
     protein, 104  
 T lymphocytes recognize genes coding for  
   antigens, 113-118  
 T-cell costimulation in tumor immunity,  
 225-229  
 T-cell epitopes in synthetic vaccines, 258  
 T-cell immunity to oncogenic proteins,  
 101-110  
 T-cell lymphoma, cutaneous, antiidiotype  
   vaccine therapy for, 376  
 T-cell recognition  
   of mucin cDNA, 231-241  
   of tumor-specific antigens, 301-302

- T-cell surveillance
  - and EBV-associated malignancies, 93-96
  - of EBV-infected cells, 89-92
- T-cell tolerance, 35-37
- TA3-Ha tumor for analysis of carbohydrate antigens, 73
- TGF- $\beta$  producing tumors, transfection of, with IL-2, 346-348
- Thymus, antigenic selection in, 35, 39
- Tissue-specific antigens and tolerance, 60
- Tolerance
  - and tissue-specific antigens, 60
  - immune, 59-60
  - and ways to break it, 34-40
- Transfection of tumors elicits tumor rejection, 346-348
- Transgenic mice, tolerance research with, 37-38
- Tumor antigens, 323-325
  - human, 27-29
  - immunogenic, 59
  - in man, 50-55
  - improving cellular immunity to, 325-328
  - in breast cancer, 340-342
- Tumor escape from immune response, 42-49
- Tumor immunity
  - and peripheral tolerance, 328-329
  - costimulation in, 225-229
  - interleukin-2 and gamma-interferon in, 349-351
  - regulation of, 27
- Tumor immunogenicity, augmented, with alpha-interferon, 388-391
- Tumor immunology, 24-30
- as basis for vaccine development, 322-323
- Tumor recognition and rejection, 2
- Tumor rejection antigens
  - cancer immunotherapy with, 115-118
  - recognized by T cells, 114
- Tumor vaccines overview, 1-5
- Tumor vaccinology, foundations of, 4-5
- Tumor-associated antigens, mimicry of, 214-221

- V**accinia virus expression of cytokines, 293-294
- Vaccination, adjuvant, in colorectal carcinoma, 360-362
- Vaccine
  - antidiotype, for cutaneous T-cell lymphoma, 376-377
  - chorionic gonadotropin, in metastatic cancer, 358-359
  - for melanoma prepared from shed antigens, 190-202

- for metastatic melanoma, 120-132
- idiotype-specific, in B-cell lymphoma, 385-387
- in colorectal cancer, 135-145
- in Hodgkin-associated CD30 antigen, 352-354
- in human melanoma, 120, 147-151, 153, 167, 178, 190, 204, 214
- melanoma
  - and alpha-interferon, 388-391
  - T-cell response augmented with, 343-345
  - therapeutic, for melanoma, 378-380
- Vaccines
  - against cancer in animals, 8-9
  - antigen-specific, 307-308
  - cancer, 322-329
  - for human cancer of viral etiology, 311-319
  - for malaria and AIDS, experimental, 265-274
  - ganglioside, in melanoma, 204-211
  - GD3-conjugate, immunogenic, 396-397
  - genetically engineered, 244-253, 301-308
  - genetically modified, 306-307
  - melanoma, viral lysates in, 167-176
  - shed antigens, 190
  - synthetic, epitope selection and design of, 256-262
  - tumor cell, in colon adenocarcinoma, 331
  - vector-based, in cancer therapy, 292-298
  - viral, 6-18
  - with adjuvants, 303
- Vaccinia melanoma cell lysates, immunization with, 167, 172
- Vaccinia melanoma oncolysate for melanoma, 178-187
- Vaccinia virus
  - expression of tumor antigens, 293
  - recombinant, in tumor vaccines, 331
  - specific immunotherapy with, 370-373
- Viral antigen expression in EBV-infected cells, 86-89
- Viral etiology of human cancers, 311-312
- Viral lysates in treatment of melanoma, 167-176
- Viral vaccines against cancer, 6-18
- Virus
  - nonpropagable, 7
  - propagable, 7
  - recombinant vaccinia, immunotherapy with, 370-373
- Virus-induced tumors, 25
- VMCL, *See* Vaccinia melanoma cell lysates
- VMO, *See* Vaccinia melanoma oncolysate

- X**enobiotics in autoimmunity, 20



## Index of Contributors

**A**brams, S., 370-373  
Aldrich, W., 358-359  
Alving, C. R., 265-275  
Arlen, M., 374-375  
Armbruster, C., 360-363  
Austin, F. C., 322-330

**B**ash, J. A., 331-333  
Baurain, J.-F., 113-119  
Bedore, D. A., 392-395  
Berd, D., 147-152  
Berzofsky, J. A., 256-264  
Beverley, P., 69-79  
Bicknell, D. C., 42-49  
Bloemena, E., 135-146  
Bodmer, J. G., 42-49  
Bodmer, W. F., 42-49  
Boon, T., 113-119  
Bouchard, B., 59-68  
Browning, M. J., 42-49  
Burchell, J., 69-79  
Bystry, J.-C., xi, 190-203

**C**alves, M., 396-397  
Campbell, M., 385-387  
Carbone, A., 367-369  
Carmignani, G., 367-369  
Chang, C., 120-134  
Chapman, P. B., 59-68  
Chatterjee, M., 376-377  
Cheever, M. A., 101-112  
Chen, L., 225-230  
Chen, W., 101-112  
Chen, Z. J., 398-401  
Cole, J. S., III, 311-321  
Coulie, P., 113-119  
Cox, W. I., 292-300  
Czerwinski, D., 385-387

**D**al Bo, V., 367-369  
de Campos-Lima, P. O., 86-100  
Denton, G. W. L., 334-336  
Depisch, D., 360-363  
Desai, P. R., 355-357  
Detrick, B., 265-275  
Di Donna, D., 367-369  
Diehl, V., 352-354  
Dinstl, K., 360-363  
Disis, M. L., 101-112  
Dolcetti, R., 86-100  
Domenech, N., 231-243  
Durrant, L. G., 334-336

**E**ddy, G. A., 265-275  
Elashoff, R., 120-134  
Elliott, G. T., 378-381  
Elliott, R. L., 340-342

**F**agerberg, J., 337-339  
Famatiga, E., 120-134  
Favaro, D., 367-369  
Ferrone, S., xi, 214-224, 398-401  
Fiaccavento, G., 367-369  
Finerty, J. F., 322-330  
Finn, O. J., 231-243  
Flamand, V., 382-384  
Foon, K. A., 376-377  
Foshag, L. J., 120-134, 343-345  
Francini, M., 367-369  
Frelinger, J., 346-348, 349-351  
Frödin, J.-E., 337-339

**G**alligioni, E., 367-369  
Gavioli, R., 86-100  
Gissmann, L., 80-85  
Gochnour, D., 358-359  
Goedegebuure, P., 153-166  
Groshen, S., 153-166  
Gruber, J., 311-321  
Gupta, R. K., 120-134

**H**anna, M. G., Jr., 135-146  
Hara, I., 59-68  
Harel, W., 153-166  
Harkins, S., 349-351  
Hart, S., 385-387  
Hayashi, Y., 343-345  
Head, J. F., 340-342  
Heath, A. K., 322-330  
Helling, F., 396-397  
Hellström, I., 24-33, 225-230  
Hellström, K. E., 24-33, 225-230  
Herman, J., 113-119  
Hersey, P., 167-177  
Hilleman, M. R., 6-18  
Hofbauer, F., 360-363  
Hofman, F., 153-166  
Hollinshead, A. C., 374-375  
Hoon, D. S. B., 120-134, 343-345  
Hoover, H. C., Jr., 135-146  
Houghton, A. N., 59-68  
Hsu, F. J., 385-387  
Huang, X.-Q., 153-166  
Hutter, E., 346-348, 349-351

Irie, R. F., 120-134  
Irvine, K., 370-373

Jochmus, I., 80-85

Kan-Mitchell, J., 153-166  
Kantor, J., 370-373  
Kaufman, H., 370-373  
Kensil, C. R., 392-395  
Koeppen, H., 244-255  
Koganty, R., 276-291  
Kohler, H., 376-377  
Krausa, P., 42-49  
Kwak, L., 385-387

Lehmann, F., 113-119  
LeMay, L. G., 153-166  
Leo, O., 382-384  
Lespagnard, L., 382-384  
Levy, R., 385-387  
Lewis, M. G., 265-275  
Liebrich, W., 364-366  
Liles, T., 385-387  
Linsley, P., 225-230  
Livingston, P. O., xi, 1-5, 204-213, 396-397  
Lloyd, K. O., 50-58  
Locker, G., 360-363  
Longenecker, B. M., 276-291  
Lord, E., 346-348, 349-351

MacLean, G. D., 276-291  
Magarian-Blander, J., 231-243  
Maguire, H. C., Jr., 147-152  
Martin, E. W., 358-359  
Mastrangelo, M. J., 147-152  
Masucci, M. G., 86-100  
Mazza, G., 367-369  
McAdam, A., 346-348, 349-351  
McCoy, J. L., 340-342  
McLeod, R. A., 378-381  
Mellstedt, H., 337-339  
Miller, R., 385-387  
Mitchell, M. S., 153-166  
Morisaki, T., 343-345  
Morton, D. L., 120-134, 343-345  
Moser, M., 382-384  
Mrozek, E., 376-377  
Muller, C., 113-119  
Müller, M., 80-85

Naftzger, C., 59-68  
Nindl, I., 80-85  
Nizze, A. J., 343-345  
Nizze, J. A., 120-134  
Nossal, G. J. V., 34-41

Oettgen, H. F., 396-397  
Oseroff, A., 376-377

Paoletti, E., 292-300  
Pardoll, D. M., 301-310  
Patel, B. T., 364-366  
Peace, D. J., 101-112  
Perez, J., 378-381  
Peters, L., 135-146  
Pfreundschuh, M., 352-354  
Pohl, C., 352-354  
Politzer, P., 360-363  
Pomato, N., 135-146  
Presant, C., 388-391  
Pulaski, B., 346-348, 349-351

Quaia, M., 367-369

Ragnhammar, P., 337-339  
Rainer, H., 360-363  
Ransom, J. H., 135-146  
Rao, R., 388-391  
Reddish, M., 276-291  
Renner, C., 352-354  
Richards, R. L., 265-275  
Robins, R. A., 334-336  
Rowan, A., 42-49  
Russell, D., 376-377

Sacco, C., 367-369  
Santarosa, M., 367-369  
Scanlon, E. F., 355-357  
Schiessel, R., 360-363  
Schirrmacher, V., 364-366  
Schlag, P., 364-366  
Schlom, J., 370-373  
Schreiber, H., 244-255  
Schulte-Hermann, R., 360-363  
Shafferman, A., 265-275  
Shang, Y., 396-397  
Shen, G. L. C., 322-330  
Singh, S., 244-255  
Sivanandham, M., 178-189  
Smith, J., 388-391  
Snoy, P., 370-373  
Sogn, J. A., 322-330  
Soltysik, S., 392-395  
Spada, A., 367-369  
Spencer, B. D., 355-357  
Springer, G. F., 355-357  
Steinitz, M., 337-339  
Stewart, L., 69-79  
Stoeck, M., 364-366  
Stoll, H., 376-377  
Syrengelas, A., 385-387



**T**akahashi, M., 101-112  
 Talal, N., 19-23  
 Talamini, R., 367-369  
 Tartaglia, J., 292-300  
 Taylor-Papadimitriou, J., 69-79  
 Tegtmeyer, H., 355-357  
 Thielemans, K., 382-384  
 Triozzi, P. L., 358-359  
 Trivedi, P., 86-100  
 Tsang, K. Y., 374-375

**U**chiyama, A., 343-345  
 Ulsperger, E., 360-363  
 Urbain, J., 382-384

**V**aickus, L., 376-377  
 Vermorken, J. B., 135-146

Vetterlein, M., 360-363  
 Viggiano, S., 367-369  
 Vijayasaradhi, S., 59-68  
 Von Eschen, K. B., 378-381

**W**agner, O., 360-363  
 Waldhör, T., 360-363  
 Wallack, M. K., 178-189  
 Wanek, L. A., 120-134  
 Wang, F., 340-342  
 Weynants, P., 113-119  
 Wigzell, H., 337-339  
 Williams, T., 388-391  
 Wiseman, C., 388-391  
 Woods, F. M., 346-348  
 Wunderlich, M., 360-363

**Z**hang, Q.-J., 86-100



